X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cediranib (191) 191
index medicus (141) 141
humans (132) 132
oncology (115) 115
bevacizumab (78) 78
female (70) 70
tyrosine kinase inhibitor (63) 63
angiogenesis (60) 60
cancer (56) 56
male (53) 53
vascular endothelial growth factor (51) 51
animals (48) 48
azd2171 (45) 45
endothelial growth-factor (45) 45
middle aged (45) 45
chemotherapy (42) 42
aged (41) 41
quinazolines - therapeutic use (39) 39
pharmacology & pharmacy (38) 38
antineoplastic agents - therapeutic use (36) 36
quinazolines - administration & dosage (36) 36
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
double-blind (34) 34
treatment outcome (33) 33
vegf (33) 33
receptors, vascular endothelial growth factor - antagonists & inhibitors (31) 31
angiogenesis inhibitors - therapeutic use (30) 30
antimitotic agents (30) 30
antineoplastic agents (30) 30
research (30) 30
adult (29) 29
sunitinib (29) 29
article (28) 28
care and treatment (26) 26
hematology, oncology and palliative medicine (26) 26
combination (25) 25
medicine & public health (25) 25
mice (24) 24
drug therapy (22) 22
ovarian cancer (22) 22
quinazolines - adverse effects (22) 22
survival (22) 22
glioblastoma (21) 21
pazopanib (21) 21
tumors (21) 21
clinical trials (20) 20
colorectal neoplasms - drug therapy (20) 20
quinazolines - pharmacology (20) 20
phase-ii trial (19) 19
protein kinase inhibitors - therapeutic use (19) 19
therapy (19) 19
inhibitor (18) 18
magnetic resonance imaging (18) 18
neovascularization, pathologic - drug therapy (18) 18
sorafenib (18) 18
analysis (17) 17
tyrosine (17) 17
aged, 80 and over (16) 16
antineoplastic agents - pharmacology (16) 16
brain neoplasms - drug therapy (16) 16
cell line, tumor (16) 16
cell lung-cancer (16) 16
disease-free survival (16) 16
metastasis (16) 16
pharmacology/toxicology (16) 16
phase-ii (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
brain neoplasms - pathology (15) 15
colorectal cancer (15) 15
growth (15) 15
lung neoplasms - drug therapy (15) 15
ovarian neoplasms - drug therapy (15) 15
quinazolines - pharmacokinetics (15) 15
axitinib (14) 14
cancer therapies (14) 14
dosage and administration (14) 14
growth-factor receptor (14) 14
metastatic colorectal-cancer (14) 14
open-label (14) 14
xenograft model antitumor assays (14) 14
biomarkers (13) 13
neoplasm recurrence, local - drug therapy (13) 13
solid tumors (13) 13
angiogenesis inhibitors (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (12) 12
carcinoma (12) 12
expression (12) 12
glioblastoma - drug therapy (12) 12
health aspects (12) 12
neoplasms - drug therapy (12) 12
prognosis (12) 12
angiogenesis inhibitors - pharmacology (11) 11
cancer research (11) 11
endothelial growth factors (11) 11
glioblastoma - pathology (11) 11
gliomas (11) 11
hematology (11) 11
survival rate (11) 11
trial (11) 11
young adult (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, ISSN 1556-0864, 8/2017, Volume 12, Issue 8, pp. 1299 - 1308
Journal Article
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 10/2017, Volume 58, Issue 10, pp. 1567 - 1573
Multiparametric imaging of tumor perfusion and hypoxia with dynamic 18 F-fluoromisonidazole ( 18 F-FMISO) PET may allow for an improved response assessment to... 
Hypoxia | F-FMISO | Kinetic modeling | Perfusion | Antiangiogenesis | Cediranib | hypoxia | perfusion | 18F-FMISO | Oncology | cediranib | antiangiogenesis | kinetic modeling
Journal Article
The Oncologist, ISSN 1083-7159, 07/2019, Volume 24, Issue 7, pp. 980 - 988
Background Alveolar soft part sarcoma (ASPS) is a rare sarcoma characterized by a slow evolution, brain metastasis (BM), and resistance to doxorubicin.... 
Neoplasm drug resistance | Angiogenesis inhibitors | Neoplasm metastasis | Alveolar soft part sarcoma | CEDIRANIB | PAZOPANIB | ONCOLOGY | DOUBLE-BLIND | PATTERNS
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2013, Volume 110, Issue 47, pp. 19059 - 19064
Antiangiogenic therapy has shown clear activity and improved survival benefit for certain tumor types. However, an incomplete understanding of the mechanisms... 
Oxygen | Perfusion | Glioblastoma | Biological markers | Radiotherapy | Blood | Tissue oxygenation | Tumors | Cancer | Blood plasma | VEGFR2 | VASCULAR NORMALIZATION | BEVACIZUMAB | MULTIDISCIPLINARY SCIENCES | brain tumor | RADIATION | personalized treatment | TEMOZOLOMIDE | GROWTH-FACTOR RECEPTOR | ANTIANGIOGENIC THERAPY | AMPLIFICATION | MICROENVIRONMENT | TYROSINE KINASE INHIBITOR | Prospective Studies | Humans | Brain Neoplasms - pathology | Quinazolines | Glioblastoma - radiotherapy | Brain Neoplasms - metabolism | Oxygen - metabolism | DNA Repair Enzymes - metabolism | Dacarbazine - analogs & derivatives | Polymerase Chain Reaction | Statistics, Nonparametric | Glioblastoma - metabolism | Brain Neoplasms - radiotherapy | Tumor Suppressor Proteins - metabolism | DNA Modification Methylases - metabolism | Enzyme-Linked Immunosorbent Assay | Angiogenesis Inhibitors - pharmacology | Treatment Outcome | Brain Neoplasms - drug therapy | Receptor Protein-Tyrosine Kinases - metabolism | Biomarkers, Tumor - blood | Magnetic Resonance Imaging | Glioblastoma - pathology | Protein Kinase Inhibitors - pharmacology | Glioblastoma - drug therapy | Cancer patients | Chemotherapy | Patient outcomes | Physiological aspects | Dosage and administration | Drug therapy | Glioblastoma multiforme | Methods | Cediranib | Index Medicus | Biological Sciences
Journal Article
AMERICAN JOURNAL OF NEURORADIOLOGY, ISSN 0195-6108, 08/2014, Volume 35, Issue 8, pp. 1503 - 1508
BACKGROUND AND PURPOSE: Dynamic contrast-enhanced MR imaging can provide in vivo assessment of the microvasculature in intracranial tumors. The aim of the... 
GLIOMAS | CEREBRAL BLOOD-VOLUME | PHYSIOLOGY | CEDIRANIB | T-2-ASTERISK-DOMINANT EXTRAVASATION CORRECTION | TUMORS | NEUROIMAGING | CLINICAL NEUROLOGY | LEAKAGE CORRECTION | VASCULAR INPUT FUNCTION | GRADE | CENTRAL-NERVOUS-SYSTEM | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 01/2014, Volume 11, Issue 1, pp. 2 - 2
Journal Article
CANCER, ISSN 0008-543X, 07/2014, Volume 120, Issue 14, pp. 2164 - 2173
BACKGROUND: The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF)... 
SURVIVAL | LEUCOVORIN | angiogenesis | NITRIC-OXIDE SYNTHASE | INOS | cediranib | FLUOROURACIL | COMBINATION | phase 1 | MELANOMA | CIRCULATING TUMOR-CELLS | ONCOLOGY | bevacizumab | TYROSINE KINASE INHIBITOR
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 14, pp. 2972 - 2978
Abstract Background Poly(ADP-ribose) polymerase (PARP)-inhibitors and anti-angiogenics have activity in recurrent ovarian and breast cancer; however, the... 
Hematology, Oncology and Palliative Medicine | PARP-inhibitor | Breast | Olaparib | Ovarian | Phase 1 | Anti-angiogenic | Cediranib | CELLS | SOLID TUMORS | BEVACIZUMAB | DOWN-REGULATION | BRCA1 | HYPOXIA | RAD51 | ONCOLOGY | HOMOLOGOUS RECOMBINATION | DNA-REPAIR | Piperazines - administration & dosage | Receptors, Estrogen - metabolism | Nausea - chemically induced | Tablets | Humans | Middle Aged | Ovarian Neoplasms - pathology | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Fatigue - chemically induced | Diarrhea - chemically induced | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Capsules | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Quinazolines - administration & dosage | Ovarian Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Treatment Outcome | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoplasms, Glandular and Epithelial - drug therapy | Quinazolines - adverse effects | Carcinoma, Ovarian Epithelial | Aged | Phthalazines - adverse effects | Antimitotic agents | Product development | Breast cancer | Antineoplastic agents | Vascular endothelial growth factor | Sugars | Monosaccharides | Index Medicus
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 10/2017, Volume 58, Issue 10, pp. 1567 - 1573
Multiparametric imaging of tumor perfusion and hypoxia with dynamic F-18-fluoromisonidazole (F-18-FMISO) PET may allow for an improved response assessment to... 
hypoxia | HEAD | CONTRAST-ENHANCED MRI | perfusion | F-18-FMISO | ANGIOGENESIS | cediranib | NECK-CANCER | REPRODUCIBILITY | kinetic modeling | POSITRON-EMISSION-TOMOGRAPHY | F-18 FLUOROMISONIDAZOLE | SUNITINIB | AZD2171 | antiangiogenesis | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | PET
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 09/2018, Volume 13, Issue 9, pp. 1269 - 1283
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the... 
Biomarkers | Chemotherapy | Oncology therapeutics | Malignant pleural mesothelioma | Immunotherapy | INDUCTION CHEMOTHERAPY | OPEN-LABEL | HEMITHORACIC RADIATION | PHASE-II TRIAL | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | RESPIRATORY SYSTEM | EXTRAPLEURAL PNEUMONECTOMY | SERUM MESOTHELIN | BETA GENE-TRANSFER | GERMLINE BAP1 MUTATIONS
Journal Article